Research Features Magazine Highlights Captozyme's CSO

The biotechnology company Captozyme is spearheading an innovative approach to nutrition to prevent the formation of painful kidney stones and other complications arising from the absorption of calcium oxalate from food. The company’s research efforts are led by Dr Qing-Shan Li, co-founder and CSO of the company. 

Oxalate, a plant-based dietary substance with no known positive effects on the human body, is responsible for several debilitating health problems. These include the painful condition known as kidney stones. Dr Qing-Shan Li and associates at the biotechnology company Captozyme ( are dedicated to the prevention and treatment of these problems.